Navigation Links
Pfenex Reports Second Quarter 2014 Results and Provides Business Update
Date:8/29/2014

SAN DIEGO, Aug. 29, 2014 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of high-value and difficult to manufacture proteins including biosimilar therapeutics, today provided a business update and reported financial results for the second quarter ended June 30, 2014.

"With the successful completion of our initial public offering, we have the capital to continue to advance our biosimilar product candidates, derived from our proprietary protein expression platform," stated Bertrand C. Liang, chief executive officer of Pfenex. "We expect to complete the phase 1b/2a trial for our lead product candidate, PF582, a biosimilar to Lucentis, by the end of 2014 and initiate the phase 3 trial in mid-2015." 

Business Updates

  • On July 29, 2014 we closed our initial public offering.  Including the underwriters exercise of their option to purchase additional shares, 9,429,084 shares of common stock were sold in the offering for a total capital raise of approximately $52.6 million after underwriter fees and discounts but before deducting offering expenses.
  • With the close of our initial public offering, Pfenex expanded the leadership team through the addition of two new board members, William R. Rohn and Philip R. Schneider. Mr. Rohn joined the board as chairman and brings extensive biotech industry experience having served in managerial roles at Biogen IDEC, IDEC Pharmaceuticals and Adria Laboratories. Mr. Schneider also joined the board with broad industry experience through previous management positions with IDEC Pharmaceuticals and Syntex Pharmaceuticals.
  • Financial Highlights for the three months ended June 30, 2014

  • Total revenue for the second quarter of 2014 was $3.3 million compared to $2.3 million in the second quarter of 2013.
    The increase in revenue was due to an increase in activity related to our Px563L product candidate development under
    '/>"/>

  • SOURCE Pfenex Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Pfenex Inc. Awards Glide Pharma Development Contract for a Solid Formulation of Recombinant Anthrax Vaccine
    2. Pfenex Inc. Awards Paragon Bioservices a Contract for cGMP Manufacturing of its Recombinant Protective Antigen (rPA), for Phase 1 Clinical Trial of its Anthrax Vaccine
    3. Pfenex Awarded Contract For Development Of Next Generation rPA-Based Anthrax Vaccine
    4. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    5. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    6. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    7. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    8. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    9. Pharmasset Reports Fiscal Year End 2011 Financial Results
    10. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    11. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2015)... , September 2, 2015 ... des Wettbewerbs BeHEARD von 2015 bekanntgeben zu können. ... Rare Genomics Institute. Biovista unterstützt mit ... für die Behandlung anderer Krankheiten als denen, für ... Laffoon und sein Team bei der Wylder ...
    (Date:9/2/2015)... , ... September 02, 2015 , ... ... and life science research, today unveiled Genedata Screener ® version 13.0 at ... in-vitro screening brings to market a rich set of new capabilities. Screener now ...
    (Date:9/1/2015)... , Sept. 1, 2015 ... cancer death in American men. One in ... and 233,000 new cases are diagnosed annually. That ... are using a powerful new technique, MRI Fusion ... and large cancer lesions, treating only the affected ...
    (Date:9/1/2015)... 2015 The Dohmen Company today announced ... MBA as Chief Science Officer (CSO) of Dohmen ... role, Dr. Floyd will lead Dohmen,s growing regulatory ... pre-commercial and post approval outsourced services in quality, ... Dr. Floyd brings decades of experience leading global ...
    Breaking Biology Technology:Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 4September Is Prostate Cancer Awareness Month 2September Is Prostate Cancer Awareness Month 3September Is Prostate Cancer Awareness Month 4Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 2Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 3
    ... Career and Technical Education (NRCCTE), funded by the Office of Vocational ... a report that focuses on the question: What Will Be the ... that centered on three questions: , , ... secondary and postsecondary instruction be articulated? , ...
    ... April 15 deCODE genetics,(Nasdaq: DCGN ) today ... the,execution of strategic alternatives currently under consideration, it has,elected ... April 15 interest,payment on its outstanding 3.5% Senior Convertible ... deCODE , deCODE is a ...
    ... office of Science, the world,s leading peer-reviewed research journal, is partnering ... a webinar on Advances in Cancer Genomics to be broadcast live ... , ... (PRWEB) April 15, 2009 -- The business office ...
    Cached Biology Technology:What Will Be the Impact of Programs of Study? 2deCODE to Utilize Grace Period for Interest Payment on Senior Convertible Notes 2Science Magazine to Host Webinar on Advances in Cancer Genomics 2Science Magazine to Host Webinar on Advances in Cancer Genomics 3
    (Date:8/25/2015)... and BELLEVUE, Wash. , Aug. ... advanced robotic systems, announced today it will unveil its ... vehicle (UGV), at the National Tactical Officers Association Conference ... The Guardian S is the first-ever commercially available ... years of research and in-field trials and is protected ...
    (Date:8/20/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market and creator of ... Smart Card Alliance and the EMV Migration Forum.  ... Smart Card Alliance Latin America (SCALA) Chapter provides NXT-ID, ... thought leaders promoting adoption of smart card technology. ...
    (Date:8/12/2015)... MINNETONKA, Minn. , Aug. 12, 2015   ... that supports the entire spectrum of clinical research, is ... ™ , the company,s comprehensive SaaS-based eClinical technology platform, ... growth during the first two quarters of 2015.   ... and second largest quarters measured by contract value sold ...
    Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2
    ... - the European eel ( Anguilla anguilla ) has always been ... for millennia, the origin of the eel has long been shrouded ... fresh and coastal waters, spawning and the birth of the larvae ... about 4500 km away from the European coastlines. "Because the observation ...
    ... This news release is available in Spanish ... introduction of environmental fiscal reform would have on an economic system has ... this type have until now failed to take the informal economy into ... example, could account for as much as 20-25% of GDP. The group ...
    ... and Boston, MA; Los Angeles, CA; Mexico City, Mexico. Wed. ... Mexico and the United States has uncovered a new genetic ... 2 diabetes, particularly the elevated risk among Mexican and other ... SIGMA (Slim Initiative in Genomic Medicine for the Americas) Type ...
    Cached Biology News:The fate of the eels 2The fate of the eels 3Environmental fiscal reform would improve the environment and reduce the informal economy 2Environmental fiscal reform would improve the environment and reduce the informal economy 3New genetic risk factor for type 2 diabetes revealed 2New genetic risk factor for type 2 diabetes revealed 3New genetic risk factor for type 2 diabetes revealed 4
    ... DeCypher combines enterprise-scale sequence analysis software with ... bioinformatics analyses. With DeCypher, you can perform searches ... ESTs vs NCBI NT database in under 6 ... to genomic DNA Use HMM analysis ...
    ...
    Mouse polyclonal antibody to ALS2CR8 - amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 8...
    ...
    Biology Products: